Abstract:Background The activation of P2Y 14 receptor (P2Y 14 R) promotes osteoclast formation and causes neuropathic pain, exhibiting possible link to osteoarthritis (OA). Given lack of P2Y 14 R antagonist, the present study aims to search a novel P2Y 14 R antagonist with low toxicity and high activity from natural products as a possible drug candidate in treatment of OA. Methods The role of P2Y 14 R on OA was verified using P2Y 14 R knockout (KO) rats. Molecular docking virtual screening strategy and activity test in P2Y 14 R stably-expressed HEK293 cells were used to screen target compound from natural product library. The MM/GBSA free energy calculation/decomposition technique was used to determine the principal interaction mechanism. Next, the binding of target compound to P2Y 14 R was examined using cellular thermal shift assay and drug affinity responsive target stability test. Finally, the therapeutic effect of target compound was performed in monosodium iodoacetate (MIA)-induced OA mouse model. To verify whether the effect of target compound was attributed to P2Y 14 R, we establish the osteoarthritis model in P2Y 14 R KO mice to perform pharmacodynamic evaluation. Importantly, to investigate the potential mechanism by which target compound attenuate OA, expressions of the major transcription factors involved in osteoclast differentiation were detected by western blot, while markers of nerve damage in dorsal root ganglion (DRG) were evaluated by RT-qPCR and immunofluorescence techniques. Results Deficiency of P2Y 14 R alleviated pain behavior and cartilage destruction in MIA-induced OA rats. 14 natural compounds were screened by Glide docking-based virtual screening, among which paederosidic acid exhibited the highest antagonistic activity to P2Y 14 R with IC 50 of 8.287 μM. As a bioactive component extracted from Paederia scandens, paederosidic acid directly interacted with P2Y 14 R to enhance the thermostability and decrease the protease sensitivity of target protein, which significantly inhibited receptor activator for nuclear factor-κB ligand (RANKL)-mediated osteoclastogenesis. More importantly, paederosidic acid suppressed osteoclast formation by downregulating expressions of NFAT2 and ATP6V0D2, as well as relieved neuropathic pain by decreasing expressions of CGRP , CSF1 and galanin in DRG. Conclusions Paederosidic acid targeted P2Y 14 R to improve OA through alleviating osteoclast formation and neuropathic pain, which provided an available strategy for developing novel drug leads for treatment of OA.

Discovery of Novel and Potent P2Y14R Antagonists Via Structure-Based Virtual Screening for the Treatment of Acute Gouty Arthritis

Discovery and Computational Studies of 2-Phenyl-benzoxazole Acetamide Derivatives As Promising P2Y14R Antagonists with Anti-Gout Potential

Design, Synthesis and Evaluation of 3-Amide-5-aryl Benzoic Acid Derivatives As Novel P2Y14R Antagonists with Potential High Efficiency Against Acute Gouty Arthritis.

Beneficial Properties and Mechanisms of Natural Phytochemicals to Combat and Prevent Hyperuricemia and Gout

Z1456467176 Alleviates Gouty Arthritis by Allosterically Modulating P2X7R to Inhibit NLRP3 Inflammasome Activation

HQL6 Serves As a Novel P2Y14 Receptor Antagonist to Ameliorate Acute Gouty Arthritis Through Inhibiting Macrophage Pyroptosis.

Recent Progress on the Discovery of P2Y14 Receptor Antagonists.

Discovery of N-Substituted Acetamide Derivatives as Promising P2Y 14 R Antagonists Using Molecular Hybridization Based on Crystallographic Overlay

Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y 14 R antagonist

Identification of O-arylated huperzinines as novel cholinergic anti-inflammatory pathway agonists against gout arthritis

Structure-Based Virtual Screening for Discovery of Paederosidic Acid from Paederia Scandens As Novel P2Y14R Antagonist

Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout

Design, Synthesis and Anti-Inflammatory Evaluation of 3-Amide Benzoic Acid Derivatives As Novel P2Y14 Receptor Antagonists.

Development of Novel NLRP3-XOD Dual Inhibitors for the Treatment of Gout.

Design, Synthesis and Biological Activity Evaluation of Novel URAT1 Inhibitors

Discovery of a Series of 5-Amide-1h-pyrazole-3-carboxyl Derivatives As Potent P2Y14R Antagonists with Anti-Inflammatory Characters

Recent Advances in the Development of P2Y 14 R Inhibitors: a Patent and Literature Review (2018-Present)

Synthesis and Biological Evaluation of Novel Chlorogenic Acid-Apigenin Conjugates as Anti-acute Gout Agents

Recent advances in the development of P2Y14R inhibitors: a patent and literature review (2018-present)

Discovery of Selective P2Y6R Antagonists with High Affinity and in Vivo Efficacy for Inflammatory Disease Therapy

Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids As Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout